BRCA1 and primary biliary cholangitis: Indeed, in this study we now showed also a strong risk-reducing effect of chemotherapy in the first 5 years after PBC diagnosis on the development of new primary cancers in the contralateral breast, most notably in BRCA1 mutation carriers.